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Abstract
Background: Being able to visualize multivariate biological treatment effects can be insightful. However the axes
in visualizations are often solely defined by variation and thus have no biological meaning. This makes the effects
of treatment difficult to interpret.
Methods: A statistical visualization method is presented, which analyses and visualizes the effects of treatment in
individual subjects. The visualization is based on predefined biological processes as determined by systems-
biological datasets (metabolomics proteomics and transcriptomics). This allows one to evaluate biological effects
depending on shifts of either groups or subjects in the space predefined by the axes, which illustrate specific
biological processes. We built validated multivariate models for each axis to represent several biological processes.
In this space each subject has his or her own score on each axis/process, indicating to which extent the treatment
affects the related process.
Results: The health space model was applied to visualize the effects of a nutritional intervention, with the goal of
applying diet to improve health. The model was therefore named the ‘health space’ model. The 36 study subjects
received a 5-week dietary intervention containing several anti-inflammatory ingredients. Plasma concentrations of
79 proteins and 145 metabolites were quantified prior to and after treatment. The principal processes modulated
by the intervention were oxidative stress, inflammation, and metabolism. These processes formed the axes of the
‘health space’. The approach distinguished the treated and untreated groups, as well as two different response
subgroups. One subgroup reacted mainly by modulating its metabolic stress profile, while a second subgroup
showed a specific inflammatory and oxidative response to treatment.
Conclusions: The ‘health space’ model allows visualization of multiple results and to interpret them. The model
presents treatment group effects, subgroups and individual responses.
Background
Emerging technologies in biological research can provide
an enormous wealth of data. At the same time, researchers
are challenged to interpret this data in an integrated and
meaningful manner. Multiple parameters describe pro-
cesses and interactions between processes. Multivariate
statistical approaches like pattern recognition are applied
in the data analysis. Many multivariate visualization and
classification tools have been developed [1,2], both ‘unsu-
pervised’ and ‘supervised’ (discriminating on treatment
group). For example, principle component analysis [3,4]
(an unsupervised method) uses the largest variation in the
data to define a first axis (principle component). This
method has been shown to help structure and interpret
experiments [5]. From a biological interpretation view-
point, the drawback of this method is that the axes are
defined only by variation and therefore have no biological
meaning. Another statistical method that takes the infor-
mation on groups into account is the Partial Least Squares
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method, the first axis is defined based on the line that best
separates the defined groups. However, this method also
does not provide useful information about the underlying
biological processes. Additionally, most of these statistical
methods only separate subjects into groups and do not
provide information on the status of individual subjects
within the group. Separating, classifying and visualizing
data based on a priori defined biological processes would
greatly facilitate the biological interpretation of the data.
Examples of methods that do so are the Metabolite Set
Enrichment Analysis (MSEA), Gene Set Enrichment Ana-
lysis (GSEA) and GSEA based cluster analysis [7,8]. These
methods, however, only focus on group averages.
Since extensive phenotyping enables researchers to
accurately describe multiple aspects of a biological
response to a treatment, it is possible to apply these
results towards a personalized health strategy instead of
(or on top of) strategies based on group averages [9].
We have developed an analysis and visualization
method, named the ‘health space’, which projects subjects’
health status in a multidimensional space, based on prede-
fined multivariate parameterization of the axes. This
allows researchers to analyze responses according to the
underlying biological processes, defining the parameteriza-
tion in a biologically meaningful manner. As demonstrator
case, we applied this method to a recently published study
[10] in which relatively healthy overweight subjects were
treated in a cross-over design with a diet containing n-3
fatty acids, Epigallocatechin gallate (EGCG), Vitamin E,
Vitamin C, resveratrol, and tomato extract. The diet was
designed to improve the subjects’ health status on the
parameters inflammation, oxidation and metabolism. In
this case, the biological processes oxidative stress, meta-
bolic stress and inflammation were used to define a ‘health
space’. The plasma concentrations of 47 clinical chemistry
variables, 79 proteins and 274 metabolites before and after
a five week treatment period were analyzed, separately and
together with the transcriptome of Peripheral Blood
Mononuclear Cells (PBMC) (10812 transcripts). Only the
significantly changed parameters were used (including 7
parameters for oxidation, 18 for inflammation and 115 for
metabolism) to define the ‘health space’.
Methods
Study design, execution and analytical methods
The study has been described in detail [10]. In short, 33
males (BMI 25.5 - 35 kg/m2 and CRP 1-10 mg/L) were
treated for 5 weeks with a dietary mix (resveratrol, green
tea extract, alpha-tocopherol, vitamin C, omega-3 poly-
unsaturated fatty acids, and tomato extract) in a double
blind placebo controlled cross-over design. Measure-
ments performed on plasma were established biomarkers
(n = 47), lipidome by LC-MS (n = 108), metabolome by
GCMS (145) and multiplex quantification of 79 plasma
proteins. Transcriptomics was performed on PBMC
using Affymetrix arrays (10812 transcripts).
Axis definition
The selection of the ‘overarching processes’ oxidation,
metabolism and inflammation was adopted from the
human study [10]. The selection of significant affected
parameters and the grouping of these molecules in the
three processes are described in this reference (see [10],
Additional file 1). The mean value over time was calcu-
lated for parameters that showed significance after mul-
tiple testing. The axes contained both the t0 value and
the mean value over time for each parameter when both
were found to differ significantly between the dietary
mix group and the control group.
Statistics
‘Health’ or ‘healthy state’ was defined as the average of
the dietary mix group. This point was defined as the ori-
gin of the health space. A separate autoscaled double
cross validated PLS-DA model [6] was built for each of
the three processes, based on significantly changed clini-
cal chemistry, metabolite and protein parameters per
process (Additional file 1). To allow comparison of the
scores within a process and prevent quantitative com-
parisons between processes, the samples were scaled
such that the PLS-DA scores from the subjects treated
with the dietary mix group have mean 0 (zero) and the
scores from the control group have mean 1 (one) for all
three axes. This was performed for each individual score
for each process by subtracting the mean score of the
anti-inflammatory-dietary mix group and dividing by the
distance between the mean score of the dietary mix
group and the mean score of the placebo group. Scaling
was performed simultaneously on all scores (including
control and treated data points) of each PLS-DA model.
The overall result of this treatment was visualized by
plotting the scaled PLS-DA prediction scores in a 3D-
plot where the three processes span the axes. The axes
are statistically and biologically interdependent and are
therefore not orthogonal, but are visualized in a 3D
plot. The formation of clusters of samples inside this 3D
space was analyzed by hierarchical clustering (based on
Euclidean distance, average linkage and no additional
scaling using the Matlab Bioinformatics Toolbox V3.2
Matlab™ [11]).
A two-way ANOVA was applied to investigate the
interaction between cluster groups obtained from hier-
archical clustering and treatment. In the case of no sig-
nificant interaction, the main effects were studied. A false
discovery rate correction was applied on significant p-
values using the Benjamini and Hochberg method [12].
The null hypothesis (no effect) was rejected at the alpha
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package (versions 8.2 and 9.1; SAS Institute Inc, Cary,
NC) was used for univariate statistical analysis.
Results
Constructing the model
The plasma clinical chemistry, metabolomics and proteo-
mics results of a human nutritional intervention study
were visualized in a 3-dimensional space (Figure 1), where
the three axes represented the ‘overarching processes’ oxi-
dation, metabolism and inflammation. These processes
were shown to be affected by the treatment [10]. For these
processes p = 7, 115 and 18 parameters respectively, chan-
ged significantly (p < 0.05) due to the intervention (Addi-
tional file 1). Each subject is represented in this 3-D space
(both prior to and after treatment), based on the unique
values of these 140 metabolites and proteins. The method
is based on the construction of three PLS-DA models, one
for each of the above processes. A comparison between
scores within a PLS-DA model is meaningful, but scores
can not directly be compared between PLS-DA models. In
order to compare the scores per process, the scores of the
three models were subsequently scaled around zero (the
average of the dietary-mix group) and one (average of the
placebo group). The difference between 0 and 1 was used
to separate out relatively healthy subjects from less healthy
subjects, assuming that people become healthier using the
anti-inflammatory mix. This is further described in the
methods section.
Analysis and visualization of the effects of the anti-
inflammatory mix showed a separation between the trea-
ted and control groups, suggesting an average treatment
effect. This is logical, since the axes were constructed
using all parameters that changed significantly for the
average study group. The unique feature of this visualiza-
tion model, however, is that the changes were visualized
and directly correlated to the relevant biological processes
(metabolism, oxidation and inflammation). Overall, a
treatment related shift was observed along the predefined
inflammation and metabolism axes, and to a lesser extent
along the oxidation axis. This is emphasized by the 2-D
projections in Figure 1. Note that the process oxidation
contained fewer parameters (Additional file 1).
In addition to the group treatment effect, strong dif-
ferences in inter-individual responses were visualized
(i.e., the length of the vector is different, but the direc-
tion is similar).
Dietary compounds have a marked effect on the
response
As the health space model is partly based on metabolic
profiles, plasma metabolites derived from the dietary
intervention itself might interfere with the division into
groups. These metabolites would thus report on the diet
effect in plasma rather than on the resulting change in
metabolism or related health status. Therefore, we rebuilt
the health space without the dietary metabolites (omega-
3 PUFAs, 2,3,4,-trihydroxybutanoic acid and vitamin E).
After excluding the dietary metabolites, we built two
models, one using metabolomics and proteomics data
(Figure 2) and a second additionally including PBMC
transcriptomics data (Figure 3). Both models made it
possible to distinguish the placebo- and dietary interven-
tion groups, showing that the health space could be used
for different data types. However, since the classification
of transcripts in the selected functional groups (metabo-
lism, oxidation and inflammation) requires improvement
and the selection of the processes oxidation, inflamma-
tion and metabolism as axes is based on proteomics and
metabolomics data [10], we further focus on the health
space based only on significantly changed proteins and
metabolites.
In the model, based on metabolomics and proteomics
data and excluding the dietary metabolites, it was possi-
ble to distinguish the placebo group from the dietary-mix
treated group (Figure 2). Oxidative stress did not signifi-
cantly contribute to separating the two groups in the new
health space. This indicated that the dietary compounds
vitamin E and 2,3,4-trihydroxybutanoic acid were the
only oxidative parameters that distinguished the placebo
from the dietary-mix group in the initial model including
dietary compounds. As in the initial health space model,
the intensity of the response (length of the vector) dif-
fered between subjects. In contrast to the initial model,
the contribution of the different processes (direction of
the vector) varied between subjects; some people only
responded on the inflammation axis, whereas others only
responded on the metabolic stress axis. Subject 33 for
instance reacted primarily on the metabolism axis. Sub-
ject 1 responded on the oxidative axis. Subject 25 showed
a combined response on the oxidation and metabolism
axes (see also Figure 4). Subject 14 was already within the
“improved health area” before the dietary-mix treatment.
He had very high C20:5-ChE, C22:6-ChE and poly-unsa-
turated TG’s, which have large loadings in the metabolic
PLS-DA model. This is why the fish oil in the dietary-
mix scarcely improved Subject 14’s metabolic status. Sub-
ject 1 responded differently on dietary-mix as compared
to the other subjects, as shown by the vector facing in a
different direction (Figure 2). This subject had a much
higher concentration of plasma VCAM-1 and a lower
concentration of M-CSF than average, both after taking
the placebo and the dietary mix. He also had relatively
high alanine transaminase (ALT) and albumin levels.
After taking the placebo, subject 19 showed very different
levels of inflammatory parameters compared to the other
subjects. The levels of Beta2-microglobulin and uric acid
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after the placebo period than after the dietary-mix period.
The intervention response of the subjects can be
grouped
The individual response was defined as the individual dif-
ference between the placebo and the anti-inflammatory
m i xo nt h et h r e ea x e s .T h ei n d i v i d u a lr e s p o n s et ot h e
dietary treatment on the three different processes was
clustered in two main groups (Figure 4). Subjects in
group 1 mainly showed changes in the inflammation and
oxidation parameters. Subjects in group 2 had primarily a
metabolic response. Note that oxidation did not separate
between the dietary-mix group and the placebo groups,
but is important in defining the clusters. The two respon-
der groups we identified did not significantly differ in
Figure 1 Health space model with dietary compounds. Double-cross validated PLS-DA model for each process on an axis and based on
significantly changed parameters in the process (metabolism; n = 115, inflammation; n = 18; oxidation; n = 7). Note that each process contained
a different number of parameters. The model is scaled around 0 for the treated group and 1 for the untreated group. A: 3-D representation B&C:
2-D representation.
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post-weight or in bodyweight change. The molecules pri-
marily responsible for the separation were C20:5-choles-
terol ester, C22:6-cholesterol ester, indole-3-propionic
acid, uric acid and arachidonic acid. Indole-3-propionic
acid (IPA) had a significant interaction effect. This means
that the levels of IPA were affected by the anti-inflamma-
tory treatment in group 1 but not in group 2.
Figure 2 Health space model without dietary compounds. Double-cross validated PLS-DA model for each process on an axis and based on
significantly changed parameters in the process without the dietary compounds (metabolism; n = 114, inflammation; n = 15; oxidation; n = 5).
Note that each process contained a different number of parameters. The model is scaled around 0 for the treated group and 1 for the untreated
group. A: 3-D representation B&C: 2-D representation.
Bouwman et al. BMC Medical Genomics 2012, 5:1
http://www.biomedcentral.com/1755-8794/5/1
Page 5 of 9Discussion
We present a method that analyses and visualizes indivi-
duals’ health status and their treatment response as
derived from multiple, multi-omics parameters of prede-
fined biological processes. Using this method, we
showed that an anti-inflammatory dietary intervention
lead to significant average changes in plasma parameters
and that unique individual responses could also be iden-
tified. These inter-individual responses were clustered
into two distinct subgroups.
Figure 3 Health space model including transcriptomics data. Health space including transcriptomics data. Double-cross validated PLS-DA
model was built for each process on an axis based on significantly changed parameters in the process without the dietary compounds
(metabolism; n = 154, inflammation; n = 37; oxidation; n = 10). A: 3-D representation B&C: 2-D representation.
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health space) did not depend on age, BMI, order of
treatment, waist-hip ratio, pre-weight, post-weight or on
bodyweight change. The sub-group analysis revealed
that individual treatment responses differed from the
average group response. For instance, the treatment
effect on plasma indole-3-propionic acid concentration
was different between the two subgroups. Indole-3-pro-
pionic acid is a metabolite that originates from intestinal
microbiota [13]. Changes in this metabolite suggest
adjustments in size or composition of the intestinal flora
after dietary-mix intervention in subjects from respon-
der group 1. The data suggest that the changes in intest-
inal flora occurred in subjects in group 1, but not in
group 2.
The health space also reveals some personalized
responses to the dietary intervention. Subject 14, for
instance, was already in the improved health group when
taking placebo, as a result of relatively high concentrations
of fish-oil related parameters. This suggests that this
person consumed more fish than average. Additionally,
subject 1 responded differently than the other subjects.
High plasma ALT and albumin concentrations indicated a
biliary obstruction in this subject. A reduction in bile acid
release may also reduce the absorption of fatty acids (and
lipids and fat soluble vitamins) from the intestine and
cause the observed lack in metabolic response. Moreover,
this person had a high pro-oxidative-stress response which
is known to be related to biliary obstruction [14,15]. Also,
the position of subject 19 in the health space was distinctly
different than the others. Subject 19 was diagnosed with a
malignant tumor (Kahler’s disease) two months following
the study. This disease may have caused the high levels of
VCAM-1 in this subject. The increase of uric acid [16]
and beta2-microglobulin [17] after the second period (for
this subject the placebo period) indicate the onset of renal
dysfunction during the study, which is a known complica-
tion of this disease.
The current version of the method builds PLS-DA
models for the fold changes of the different parameters
Figure 4 Hierarchical clustering of individual response. Hierarchical clustering of individual response of the subjects on the three processes.
Every person has his individual change in all three processes within the ‘health space’. The individual change for every subject is indicated per
process (fig 3B) and clustered according to the resulting score pattern (fig 3A). Person 19 is an outlier and not used for further analysis. Two
main groups can be distinguished.
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method presumes that the importance of changes in
plasma concentration is relative to the size of the
change. This may not necessarily be correct. Certain
minor plasma metabolite or protein changes may have
large biological consequences, while other large
changes may be of little biological relevance. This
effect can be taken into account by including additional
biological information, e.g. by weighting the compo-
nents in the different axes. The current model includes
only those parameters that significantly changed in the
group average analysis. This may underestimate para-
meters that were affected on an individual basis, i.e.
the metabolites and proteins that may be important for
personalized health. A model variant may thus include
all measured parameters relevant to the selected biolo-
gical processes, instead of only the significantly chan-
ged processes. Another variant being developed
includes multivariate feature selection by bootstrapping
to select the most significant factors.
In this example of the ‘health space’ model, we used
the processes metabolism, oxidation and inflammation.
Some molecules are represented in more than one
process (Additional file 1). This way we could take
into account that the processes are biologically
interdependent.
In the current example, ‘health’ was simply defined
as the average state of metabolism, oxidation and
inflammation after the anti- inflammatory intervention
(the origin of the model). This demonstrates the
applicability of the model. Of course, ‘health’ should be
more accurately defined as a more absolute center (the
origin) of the ‘health space’ model. Furthermore,
genetic, life stage and environmental factors influence
the chosen biological processes and have an impact on
(optimal) health. Other biological processes may be
taken into consideration. Multiple studies could be
analyzed to more precisely define and refine the health
space.
Conclusions
’Health space’ allows scientists to visualize multiple
results in a biologically relevant way. This visualization
then aids the interpretation of these results. This model
presents the effects of treatment, as well as subgroup
and individual responses. The practical advantages of
this application within a single study are obvious, as this
is to our knowledge the first multivariate statistical
approach that quantifies and visualizes multiple molecu-
lar changes in a biological context and at an individual
subject level. Since the model is applicable for any pre-
defined set of biological axes, it can be applied in a wide
range of (systems) biology studies.
Additional material
Additional file 1: Parameters used to define the axes for
inflammation, metabolism and oxidation (d = from diet). Per
parameter p-values and platform type are indicated (derived from Bakker
et al.). An empty cell means no data available, ns = not significant, M =
metabolomics, P = proteomics, C = clinical data.
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